Koh M S, Irving L B
Department of Respiratory and Sleep Medicine, Royal Melbourne Hospital, Melbourne, Vic., Australia.
Int J Clin Pract. 2007 Aug;61(8):1375-9. doi: 10.1111/j.1742-1241.2007.01410.x. Epub 2007 Jun 22.
Although mild asthmatics form the majority of asthma sufferers, there is a relative paucity of evidence-based treatment compared with severe asthmatics.
We have performed an up-to-date review of the literature on therapy in this group of patients who form an overlooked but important majority. Potential trials were identified through MEDLINE (1965-2007) and Cochrane library (up to February 2007).
Recent trials have shown that inhaled corticosteroids (ICS) remain the cornerstone of treatment for patients with mild persistent asthma. Early intervention with ICS decreases the risk of severe exacerbations and improves asthma control in patients with mild persistent asthma of recent onset. ICS are superior to leukotriene receptor antagonists and xanthines for control of asthma and in the improvement of lung functions. The addition of long-acting beta2-agonist may be considered in those with moderately persistent asthma or whom asthma is not well controlled with low doses of ICS.
尽管轻度哮喘患者占哮喘患者的大多数，但与重度哮喘患者相比，基于证据的治疗相对较少。
我们对这一被忽视但占重要多数的患者群体的治疗文献进行了最新综述。通过MEDLINE（1965 - 2007年）和Cochrane图书馆（截至2007年2月）确定了潜在的试验。
近期试验表明，吸入性糖皮质激素（ICS）仍然是轻度持续性哮喘患者治疗的基石。对近期发病的轻度持续性哮喘患者早期使用ICS可降低严重发作的风险并改善哮喘控制。在控制哮喘和改善肺功能方面，ICS优于白三烯受体拮抗剂和黄嘌呤类药物。对于中度持续性哮喘患者或低剂量ICS治疗效果不佳的哮喘患者，可考虑加用长效β2激动剂。
